Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Bharat Immunologicals & Biologicals Corporation Ltd.
Source DateBoard Meeting DateDetails
07-Aug-2024 16-Aug-2024 General Purpose.
29-Feb-2024 08-Mar-2024 General Purpose
19-Oct-2023 31-Oct-2023 Quarterly Results
17-Apr-2023 24-Apr-2023 Audited Results
01-Feb-2023 09-Feb-2023 Quarterly Results
06-Oct-2022 17-Oct-2022 Quarterly Results
03-Aug-2022 11-Aug-2022 Quarterly Results
18-May-2022 30-May-2022 Audited Results
31-Jan-2022 08-Feb-2022 Quarterly Results
22-Oct-2021 29-Oct-2021 Quarterly Results
23-Jul-2021 27-Jul-2021 BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2021 ,inter alia, to consider and approve It is submitted that the intimation for date of Board Meeting was submitted at Exchange for 22.07.2021. However due to unavoidable circumstances it has been postponed to 27.07.2021.
15-Jul-2021 22-Jul-2021 Inter alia, to consider and approve the accounts of the Company for the period ended 31st March 2021.
03-Feb-2021 10-Feb-2021 Quarterly Results
22-Dec-2020 30-Dec-2020 Quarterly Results & A.G.M. Inter alia, to consider and approve Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 30th December 2020, to approve the Unaudited Quarterly Financial Results of the Company for the quarter ended 30th September 2020 and to approve the Annual Report 2019-20.
04-Sep-2020 11-Sep-2020 Quarterly Results
10-Jul-2020 20-Jul-2020 Audited Results
23-Jan-2020 31-Jan-2020 Quarterly Results
15-Oct-2019 29-Oct-2019 BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2019 ,inter alia, to consider and approve Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 29th October 2019, to approve and take on record the Un-audited Quarterly Financial Results of the Company for the quarter and half year ended 30th September 2019.
25-Jul-2019 01-Aug-2019 BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2019 ,inter alia, to consider and approve Madam/Sir, Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 1st August 2019, to approve and take on record the Un-audited Quarterly Financial Results of the Company for the quarter ended 30th June 2019. Requested to take the above on record please.
04-Apr-2019 11-Apr-2019 BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/04/2019 ,inter alia, to consider and approve Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 11th April 2019, to approve and take on record the Un-audited Quarterly Financial Results of the Company for the quarter ended 31st March 2019.
Page 1 of 4
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.